Overview

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company
ImClone LLC

Collaborator:

Bristol-Myers Squibb

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cetuximab
Paclitaxel